Results 1 to 10 of about 17,377 (218)

A case of cardiac amyloidosis incidentally detected by bone scintigraphy [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2021
A 73-year-old man with lung cancer underwent bone scintigraphy for disease staging. Diffuse myocardial technetium hydroxymethylene diphosphonate (99mTc-HMDP) uptake was incidentally found.
Hiroki Tanaka, Makoto Hosono, Mitsunori Kanagaki, Marina Shimizu, Naoko Matsubara, Kazuna Kawabata, Tadashi Miyamoto, Kazumi Itoi   +7 more
doaj   +1 more source

Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records

ESC Heart Failure, 2023
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM), a progressive and fatal cardiomyopathy, is frequently misdiagnosed or entails diagnostic delays, hindering patients from timely treatment.
Ana Moya, Clara L. Oeste, Monika Beles, Sofie Verstreken, Riet Dierckx, Ward Heggermont, Jozef Bartunek, Eline Bogaerts, Imke Masuy, Dries Hens, Dario Bertolone, Marc Vanderheyden   +11 more
doaj   +1 more source

Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an underdiagnosed cause of heart failure (HF) among patients ≥60 years of age. Although the V122I (valine to isoleucine substitution at position 122 of the transthyretin protein) variant ...
Avni Madhani, Natalia Sabogal, Daniel Massillon, Ludwine D. Paul, Carlos Rodriguez, Denise Fine, Stephen Helmke, Morgan Winburn, Damian Kurian, Farbod Raiszadeh, Sergio Teruya, Elizabeth Cohn, Andrew J. Einstein, Edward J. Miller, Lawreen H. Connors, Mathew S. Maurer, Frederick L. Ruberg   +16 more
doaj   +1 more source

Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience

Frontiers in Cardiovascular Medicine, 2023
AimsTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy. Treatment options in patients with advanced ATTR-CM are limited to cardiac transplantation (CT).
Yousuf Razvi, Aldostefano Porcari, Aldostefano Porcari, Concetta Di Nora, Rishi K. Patel, Adam Ioannou, Muhammad U. Rauf, Ambra Masi, Steven Law, Liza Chacko, Tamer Rezk, Sriram Ravichandran, Janet Gilbertson, Dorota Rowczenio, Iona J. Blakeney, Nandita Kaza, David F. Hutt, Helen Lachmann, Ashutosh Wechalekar, William Moody, Sern Lim, Colin Chue, Carol Whelan, Lucia Venneri, Ana Martinez-Naharro, Marco Merlo, Gianfranco Sinagra, Ugolino Livi, Philip Hawkins, Marianna Fontana, Julian D. Gillmore   +30 more
doaj   +1 more source

Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up

BMC Cardiovascular Disorders, 2023
Background Recent studies have reported atrial involvement and coexistence of aortic stenosis in transthyretin (ATTR) cardiac amyloidosis (CA). However, pathological reports of extraventricular ATTR amyloid deposits in atrial structures or heart valves ...
Atsushi Okada, Takashi Kakuta, Naoki Tadokoro, Emi Tateishi, Yoshiaki Morita, Takeshi Kitai, Makoto Amaki, Hideaki Kanzaki, Keiko Ohta-Ogo, Yoshihiko Ikeda, Satsuki Fukushima, Tomoyuki Fujita, Kengo Kusano, Teruo Noguchi, Chisato Izumi   +14 more
doaj   +1 more source

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

ESC Heart Failure, 2022
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR). The aim of this study was to estimate healthcare resource use for ATTR‐CM patients compared with heart failure (HF) patients, in Denmark,
Rosa Lauppe, Johan Liseth Hansen, Anna Fornwall, Katarina Johansson, Mark H. Rozenbaum, Anne Mette Strand, Merja Vakevainen, Johanna Kuusisto, Einar Gude, J. Gustav Smith, Finn Gustafsson   +10 more
doaj   +1 more source

Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction.

PLoS ONE, 2021
AimTransthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) with preserved left ventricular ejection fraction (LVEF), typically presenting as restrictive cardiomyopathy.
Sorel Goland, Igor Volodarsky, Yacov Fabricant, Shay Livschitz, Sagi Tshori, Valeri Cuciuc, Liaz Zilberman, Irena Fugenfirov, Valeri Meledin, Sara Shimoni, Sagie Josfberg, Jacob George   +11 more
doaj   +1 more source

Systemic ATTR-amyloidosis, a Rare Form of Internal Organ Damage

Рациональная фармакотерапия в кардиологии, 2019
The article presents the case report of a rare hereditary form of systemic ATTR-amyloidosis in Russian patient with a discussion of approaches to the diagnosis and treatment of this form, also based on the own experience in the management of such ...
V. V. Rameev, R. P. Myasnikov, P. P. Vinogradov, L. V. Kozlovskaya, S. V. Moiseev, E. I. Fomicheva, S. A. Beregovskaya, E. A. Mershina, S. A. Kostina, L. A. Strizhakov, A. S. Rameeva, P. P. Tao, O. M. Drapkina   +12 more
doaj   +1 more source

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups

Orphanet Journal of Rare Diseases, 2021
Background Transthyretin amyloidosis, or ATTR, is a progressive and debilitating rare proteopathy generally manifested as either transthyretin amyloid polyneuropathy (ATTR-PN) or transthyretin amyloid cardiomyopathy (ATTR-CM).
David Rintell, Dena Heath, Florencia Braga Mendendez, Elizabeth Cross, Theodore Cross, Vincent Knobel, Bruno Gagnon, Cameron Turtle, Alan Cohen, Edward Kalmykov, Jonathan Fox   +10 more
doaj   +1 more source

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage

ESC Heart Failure, 2020
Aims Cardiac transthyretin amyloidosis (ATTR‐CM) is a progressive and fatal condition. Prognosis can be determined at diagnosis according to the National Amyloidosis Centre (NAC) transthyretin amyloidosis (ATTR) stage.
Steven Law, Aviva Petrie, Liza Chacko, Oliver C. Cohen, Sriram Ravichandran, Janet A. Gilbertson, Dorota Rowczenio, Ashutosh Wechalekar, Ana Martinez‐Naharro, Helen J. Lachmann, Carol J. Whelan, David F. Hutt, Philip N. Hawkins, Marianna Fontana, Julian D. Gillmore   +14 more
doaj   +1 more source